To treat osteoporosis, denosumab appears more effective than zoledronate: denosumab has the advantage in building bone density, and has fewer side effects.: An article from: Duke Medicine Health News
Book Details
Author(s)Susan E. Spratt
PublisherBelvoir Media Group, LLC
ISBN / ASINB00JDI86X8
ISBN-13978B00JDI86X2
AvailabilityAvailable for download now
Sales Rank99,999,999
MarketplaceUnited States 🇺🇸
Description
This digital document is an article from Duke Medicine Health News, published by Belvoir Media Group, LLC on March 1, 2014. The length of the article is 914 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details
Title: To treat osteoporosis, denosumab appears more effective than zoledronate: denosumab has the advantage in building bone density, and has fewer side effects.
Author: Susan E. Spratt
Publication:Duke Medicine Health News (Newsletter)
Date: March 1, 2014
Publisher: Belvoir Media Group, LLC
Volume: 20 Issue: 3 Page: 1(2)
Distributed by Gale, a part of Cengage Learning
Citation Details
Title: To treat osteoporosis, denosumab appears more effective than zoledronate: denosumab has the advantage in building bone density, and has fewer side effects.
Author: Susan E. Spratt
Publication:Duke Medicine Health News (Newsletter)
Date: March 1, 2014
Publisher: Belvoir Media Group, LLC
Volume: 20 Issue: 3 Page: 1(2)
Distributed by Gale, a part of Cengage Learning
